NCT01027598 - Randomized, Double-Blind Trial of Erlotinib/Pazopanib or Erlotinib/Placebo in Patients With Previously Treated Advanced Non-Small-Cell Lung Cancer | Biotech Hunter

Enrollment

202

Participants

Timeline

Start Date

January 31, 2010

Primary Completion Date

April 30, 2014

Study Completion Date

June 30, 2014

Conditions

Non Small Cell Lung Cancer

Interventions

DRUG

Pazopanib

Pazopanib: 600 mg orally daily

DRUG

Erlotinib

Erlotinib: 150 mg orally daily

Trial Locations (8)

Virginia Cancer Institute, Richmond

South Carolina Oncology Associates, PA, Columbia

Suburban Hem Onc, Lawrenceville

Florida Cancer Specialists, Fort Myers

Tennessee Oncology, PLLC, Nashville

Chattanooga Oncology Hematology Associates, Chattanooga

Family Cancer Center, Collerville

Oncology Hematology Care, Cincinnati